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Abstract
Purpose Although long-term colorectal cancer (CRC) survi-
vors generally report a good quality of life, fear of cancer
recurrence (FCR) remains an important issue. This study in-
vestigated whether the Cancer Worry Scale (CWS) can detect
high FCR, the prevalence, and characteristics of FCR in CRC
survivors.
Methods Two hundred and eleven patients who had under-
gone successful CRC surgery in the period 2003–2010 in
the Radboud University Medical Center in the Netherlands
were asked to participate. All patients were sent an informa-
tion letter plus questionnaires for collecting information on
demographic and medical variables, FCR, distress, and qual-
ity of life.
Results Seventy-six patients (36 %; median age of 67.7 years
range 41–88 years) completed the questionnaires a median of
5.1 years after surgery. A cut-off score of 14 or higher on the
CWS was optimal to detect high FCR. Twenty-nine patients
(38 %) experienced high levels of FCR, characterized by
higher levels of distress, post-traumatic stress symptoms,
and lower quality of life. These individuals particularly
reacted to disease-related triggers, felt helpless, were worried,
and experienced limitations in daily functioning. High FCR
was not associated with demographic or medical variables.
Conclusion Long after successful CRC surgery, FCR is a se-
rious problem that impairs the quality of life for a substantial
proportion of patients. With the CWS, it is possible to detect
high FCR and thereby assist survivors in receiving appropriate
care.
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Introduction
Early detection and improved cancer treatment have increased
the survival rate of colorectal cancer (CRC) over the past
decades [1]. This has made it important to pay attention to
the way survivors deal with chronic or late effects of the
disease and its treatment. A number of recent studies have
investigated the quality of life (QoL) of CRC survivors and
have shown that while QoL is reduced after treatment com-
pletion, it gradually improves over time in the absence of
disease recurrence or progression [2–5]. While a systematic
review found long-term CRC survivors to have good overall
QoL [6], this does not necessarily mean that these individuals
do not experience problems that can influence their daily func-
tioning. Not only can CRC survivors have specific physical
complaints, such as fecal, urinary, or sexual disorders [7], but
they might also have an unmet need for psychosocial help
with regard to fear of cancer recurrence (FCR) [8]. FCR can
be defined as the fear or worry that the disease will return or
progress in the same organ or in another part of the body [9].
While a normal level of FCR can keep a person alert and
aware of symptoms [10], high levels of FCR can adversely
affect a person’s quality of life and social activities [11–14].
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Patients may focus obsessively on symptoms [10], which can
restrict their ability to plan for the future and can lead to nu-
merous unscheduled doctor appointments [15, 16]. Among
the few studies reporting FCR in CRC survivors, the preva-
lence of high FCR ranges between 4 and 85 % [17–22]. This
wide range of percentages high FCRmight be attributed to the
fact that there is no consensus about what are clinically rele-
vant levels of FCR. Furthermore, it might be attributed to the
use of various instruments to measure FCR for which there are
few or no psychometric data or cut-off points available [10]. In
the research on FCR in CRC patients, some studies did not use
a FCR specific measure [18, 21], whereas others had lacking
data on validity [17, 19, 20]. Therewith, interpretation and
comparison of percentages high FCR is difficult. Recently, a
semi-structured interview to identify patients with clinical
levels of FCR was developed by Simard and Savard [22].
Based on this interview, cut-off scores on the severity subscale
of the Fear of Cancer Recurrence Inventory (FCRI-SF) were
determined. Therewith, it is possible to use this scale as gold
standard measure for evaluating the criterion validity of dif-
ferent FCR scales. The aim of this study is to assess the ca-
pacity of the Cancer Worry Scale (CWS), validated in a sam-
ple of breast cancer survivors [23], as an instrument to detect
high levels of FCR in a sample of CRC survivors. Further-
more, there has been little research on FCR in CRC survivors,
its characteristics, and potential risk groups, mainly because
earlier studies focused on the severity and prevalence of FCR.
There is a lack of information about what specific triggers
make survivors fearful, which strategies they use to cope with
this fear, and the concrete consequences of FCR in daily life.
This study focuses on the prevalence and characteristics of
FCR in CRC survivors.
Methods
Participants
In March 2012, participants were recruited from the Depart-
ment of Surgery, Radboud University Medical Center, Nijme-
gen in the Netherlands. CRC survivors who had been treated
with curative intent and who were disease-free (no recurrence
or metastases) 1–9 years after surgery were eligible for inclu-
sion. Participants had to be able to read and write in Dutch.
Procedure
Documented approval from the local Medical Ethics Commit-
tee was obtained prior to start of the study. Contact data of
CRC survivors were obtained by a surgeon (JW), and these
individuals were sent a letter describing the purpose of the
study and a booklet with questionnaires on demographic var-
iables and psychological factors. Participants gave their
informed consent by returning the booklet. Clinical data were
extracted from medical records by one of the researchers (SJ).
Instruments
Fear of cancer recurrence: severity
The CWS is used in research to assess concerns about devel-
oping cancer or developing cancer again and the impact of
these concerns on daily functioning. The eight items of the
CWS are rated on a 4-point Likert scale ranging from BNever^
to BAlmost always^. Scores range from 8 to 32 [24]. A diag-
nostic cut-off score of 14 or higher (sensitivity 77 %; speci-
ficity 81 %) was validated for breast cancer survivors and
indicates raised levels of FCR [23].
Fear of cancer recurrence: multidimensional aspects
The Fear of Cancer Recurrence Inventory (FCRI) was devel-
oped to assess the multidimensional aspects of FCR. The
FCRI consists of seven subscales: triggers, severity, psycho-
logical distress, coping strategies, functioning impairments,
insight, and reassurance. The 42 items are rated on a 5-point
Likert scale ranging from 0 to 4. The FCRI is a reliable and
valid self-report scale [25].
The subscale Triggers includes eight items, of which
seven assess specific situations that make one think about
the possibility of cancer recurrence; one item assesses to
what degree these situations are generally avoided. The
subscale Severity includes nine items assessing the pres-
ence, frequency, intensity and duration of thoughts associ-
ated with FCR, the perceived risk of recurrence, the legit-
imacy of worrying about cancer recurrence, and the pres-
ence of other unpleasant thoughts or images that come to
mind in association with FCR. Recently, data were provid-
ed that this subscale may also be used as FCRI-short form
to screen for clinical levels of FCR. A score of 13 or higher
was optimal for screening whereas a score of 16 or higher
was the optimal diagnostic cut-off [22]. The subscale Psy-
chological Distress includes four items for emotions fre-
quently triggered by thoughts about cancer recurrence. The
subscale Coping Strategies assesses nine strategies that
may be used to cope with FCR including denial, wishful
thinking, or cognitive avoidance.
The subscale Functioning Impairments includes six
items representing domains that can be disturbed by
FCR. The subscale Insight includes three items and as-
sesses the extent to which patients perceive their fear as
excessive or unreasonable. The subscale Reassurance in-
cludes three items representing reassurance behaviors
specific to FCR.
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Distress: cancer-specific
The Impact of Event Scale (IES) was included to assess the
frequency of intrusive and avoidant phenomena after or dur-
ing the traumatic experience of cancer. Its 15 items (scoring 0,
1, 3, 5) are divided into two dimensions: BIntrusion^ (7 items)
and BAvoidance^ (8 items). A total score of 9–25 reflects
moderate adaptation difficulties; a score higher than 26 indi-
cates serious adaptation difficulties [26, 27].
Distress: general
General distress was measured with the total score of the Hos-
pital Anxiety and Depression Scale (HADS). This question-
naire includes 14 items divided into two subscales (Depres-
sion and Anxiety), each with seven items. Higher scores indi-
cate more anxiety, depression, and psychological distress. The
HADS does not contain any somatic items that could be con-
founded with symptoms associated with a physical illness. A
total score of 11 or higher indicates high distress [28, 29].
Quality of life: cancer-related
Quality of life related to CRC was measured with the Europe-
an Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire Core 30 (QLQ-
C30) and Colorectal Cancer Module (QLQ-CR38). In this
study, only scores for the functional scales and global health
scale were analyzed. Higher scores on functional scales indi-
cate better functioning and quality of life. All scores are trans-
formed linearly and range from 0 to 100 [30, 31]. A difference
of 5–10 points was considered small, 10–20 points medium
and >20 points large [32].
Data-analyses
Prior to SPSS (version 20.0) data analysis, all relevant data
were screened for normality and showed normal distributions.
Means and frequencies were used to describe the sample. On-
ly complete data for the CWS were analyzed; incomplete data
were recorded as missing data and excluded from the analy-
ses. Receiving operating characteristics (ROC) analysis was
conducted to evaluate the performance of the CWS by provid-
ing information relevant to the full range of scores that need to
be taken into account in making a threshold for high FCR in a
population of CRC survivors. The accuracy properties sensi-
tivity, specificity, and positive and negative predictive values
were assessed at each cut-off point of the CWS against the
FCRI-SF. Furthermore, the area under the ROC curve and its
95% confidence interval were examined. To differentiate high
FCR from low FCR, an optimal cut-off point should have high
sensitivity and specificity, which maximizes the proportion of
patients whose test results are accurate [33].
Multivariate ANOVAs were performed for continuous var-
iables, to assess differences between high and low FCR, based
on the cut-off score (low ≤13; high ≥14). Chi-square analyses
were performed to assess differences between high and low
FCR with regard to categorical variables. Pearson product
moment correlations and independent sample t tests were used
to assess relations between continuous variables.
For a descriptive analysis of the FCRI scores, percentages
of responses to the individual questions were calculated. In
order to reflect the degree of involvement with a specific item,
varying from small to moderate or large, answers on the sub-
scales Triggers, Coping, and Reassurance were combined into
three answer categories: (1) Bnever/rarely ,^ (2)Bsometimes^,
and (3)Bmost of the time/all the time^. Answers on the sub-
scales Severity, Psychological Distress, Functioning Impair-
ments, and Insight were also divided into three answer cate-




Of 211 CRC survivors asked to participate in the study, 80
(38 %) returned the questionnaires, and 76 (36 %) of whom
completed the CWS and were included in the analyses. There
was no difference between responders and non-responders
with regard to gender (Χ2 (1, 211)=0.03, p=0.87), but non-
responders were significantly older (t(209)=2.0, p=0.046).
Table 1 shows the demographic and medical characteristics
of the responders.
ROC analysis
The area under the curve of the ROC analysis showed a 92 %
(p<0.001; 95%CI=0.85–0.98) probability that a randomly
selected patient defined as a case by the FCRI-SF (≥16) scores
higher on the CWS than a randomly selected patient defined
as a non-case (Fig. 1). On the basis of the ROC curve, the
optimal cut-off score to differentiate between high FCR and
low FCR was 13 versus 14 (low ≤13, high ≥14), with a sen-
sitivity of 86 % and a specificity of 87 %. The positive and
negative predictive values were 76 and 93 %, respectively
(Table 2).
Reliability and measure of agreement
The CWS yielded a high internal consistency reliability coef-
ficient, Cronbach α=0.89. The correlation between the CWS
and FCRI-SF was r=0.85. In 87 % of the cases, there was
agreement between the CWS and FCRI-SF concerning the
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presence or absence of a FCR diagnosis reflecting a Cohen’s
kappa of 0.71 (SE 0.09).
Reliability
Prevalence and multidimensional aspects of high FCR
According to the established cut-off point of 14 or higher on
the CWS, 29 survivors (38 %) had high levels of FCR. These
individuals experienced significantly more psychological dis-
tress, functional impairments, and triggers, showed more in-
sight, and sought reassurance more often than the individuals
with lower levels of FCR (Table 3).
Relationship between FCR and demographic and medical
variables
There were no differences in age (t(74)=1.58, p=0.12) or time
since surgery (t(74)=−0.31, p=0.76) between survivors with
high or low levels of FCR. Chi-square tests showed categor-
ical demographic (gender, partnership, children, educational
level, employment status) and medical variables (location of
tumor, stoma, disease stage, additional treatment) not to be
associated with FCR.
Relationship between FCR and distress
Survivors with high levels of FCR experienced significantly
more general distress (t(73)=−5.4, p<0.001) and cancer-
specific distress (t(26.5)=−3.9, p=0.001) characterized by
post-traumatic stress symptoms including significantly more
int rusive ( t (31.3) =−3.8 , p = 0.001) and avoidant
Table 1 Sample characteristics (n=76)
Age (years) Median 67.3; range=41–88
Sex: male 40 53 %
Marital status
Married/partnership 55 72 %
Not in partnership 21 28 %
Children: yes 64 84 %
Educational level
Primary 03 04 %
Secondary 43 57 %
Tertiary 25 33 %
Other 05 07 %
Employment status
Retired 44 58 %
Employed 20 26 %
Home management 12 16 %
Unemployed/others 15 20 %
Time since surgery (years) Median 5.1; range=1.3–9.2
Location of tumor
Colon 58 76 %
Rectum 18 24 %
Stoma: yes 13 17 %
Disease stage
I 13 17 %
II 31 41 %
III 32 42 %
Additional treatment
Chemotherapy: yes 24 32 %
Radiotherapy: yes 10 13 %
Fig. 1 Receiving operating characteristics curve of Cancer Worry Scale
(CWS) scores against the FCRI-SF≥16. Labeled points correspond to the
CWS scores as follows: 1: 8 versus 9; 2: 9 versus 10; 3: 10 versus 11; 4:
11 versus 12; 5: 12 versus 13; 6: 13 versus 14; 7: 14 versus 15; 8: 15
versus 16; 9: 16 versus 17; 10: 17 versus 18; 11: 18 versus 19; 12: 20
versus 21; 13: 22 versus 23; 14: 23 versus 24
Table 2 Accuracy measures for CWS scores according to FCRI-SF
CWS cut-off Sensitivity Specificity PPV NPV
Score (%) (%) (%) (%)
8 vs 9 100 28 39 100
9 vs 10 100 45 46 100
10 vs 11 96 61 54 97
11 vs 12 91 72 61 94
12 vs 13 91 81 69 95
13 vs 14 86 87 76 93
14 vs 15 73 89 76 88
15 vs 16 59 92 76 83
16 vs 17 41 100 100 78
17 vs 18 32 100 100 76
18 vs 19 27 100 100 75
20 vs 21 18 100 100 72
22 vs 23 14 100 100 71
23 vs 24 9 100 100 70
NPV negative predictive value, PPV positive predictive value
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(t(27.2)=−4.6, p<0.001) phenomena after the traumatic expe-
rience of cancer, than did survivors with low levels of FCR
(Table 3).
Relationship between FCR and quality of life
Compared with low levels of FCR, high levels of FCR
were associated with a poorer quality of life (F(1,66)=
14.1, p<0.001) more impaired role functioning (F(1,
66)=8.7, p=0.004), emotional functioning, (F(1,66)=
24.0, p<0.001), cognitive functioning (F(1,66)=11.2, p=
0.001), and social functioning (F(1,66)=22.9, p<0.001).
Moreover, there were large (>20 points) clinically relevant
differences between survivors with a high or low FCR in
global quality of life, role functioning, emotional func-
tioning, and social functioning. Survivors with a high
FCR had significantly more problems with body image
(F(1,70)=13.7, p<0.001) and future perspective (F(1,
70)=39.6, p<0.001) than did survivors with a low FCR
(Table 3).
Descriptive analyses FCRI
Triggers Medical examinations, feeling sick or physically
unwell, and an appointment with the doctor or other health
professional were the most frequently reported triggers for
high FCR with 48, 45 and 38 % respectively reporting them
Bmost of the time^ or Ball the time^.
Psychological distress When survivors with high FCR
thought about the possibility of cancer recurrence, they felt
helpless or resign and expressed worry, fear, or anxiety with
34 and 31% respectively reporting them Bmost of the time^ or
Ball the time^.
Functioning impairments High FCR disrupted the ability to
make future plans or set life goals, relationships with partner/
family, and general quality of life with 18, 17, and 17 % re-
spectively reporting them Bmost of the time^ or Ball the time^.
Insight Most survivors with high FCR did not feel that they
worried excessively about the possibility of cancer recurrence
Table 3 Means and standard






EORTC QLQ-C30 Mean SD Mean SD p value
Global health/QoLc 77.6 (19.1) 56.7 (26.7) p<0.001
Physical functioningb 81.1 (21.9) 68.5 (30.7) p=0.052
Role functioningc 81.7 (24.1) 59.6 (38.1) p=0.004
Emotional functioningc 93.5 (11.3) 72.4 (23.9) p<0.001
Cognitive functioningb 86.5 (18.9) 68.6 (25.1) p=0.001
Social functioningc 93.7 (12.7) 62.8 (38.7) p<0.001
EORTC QLQ-CR38
Body imagec 91.4 (15.1) 70.4 (32.8) p<0.001
Sexual functioning 23.0 (22.6) 20.4 (19.8) p=0.623
Future perspectivec 88.9 (15.9) 56.8 (27.4) p<0.001
General distress
HADS total 5.5 (5.0) 13.8 (6.9) p<0.001
Cancer-specific distress
IES total 2.8 (6.3) 15.4 (14.6) p=0.001
Intrusion 1.9 (3.9) 8.2 (7.9) p=0.001
Avoidance 0.9 (2.5) 8.0 (7.4) p<0.001
FCRI
Triggers 6.3 (5.6) 15.5 (5.6) p<0.001
Psychological distress 1.9 (2.0) 7.6 (3.5) p<0.001
Functioning impairments 1.1 (2.1) 6.9 (5.3) p<0.001
Insight 0.3 (0.7) 2.1 (2.2) p<0.001
Reassurance 1.1 (2.0) 2.9 (3.1) p=0.005
a small difference 5–10 points
bmedium difference 10–20 points
c large difference>20 points
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or that other people thought they did with 76 and 86% respec-
tively reporting this Bnot at all^ or Ba little^.
Reassurance Survivors with high FCR sought reassurance
by going to the hospital or clinic for an examination or calling
their doctor or another health professional with 21 and 21 %
respectively reporting them Bmost of the time^ or Ball the
time^. Few such individuals examined themselves to see if
they have any physical signs of cancer with 10.7 % reporting
this Bmost of the time^ or Ball the time^.
Coping strategies Survivors with high FCR coped with this
fear by trying to convince themselves that everything would
be fine or think positively, trying to find a solution, and trying
to replace this thought with a more pleasant with 39, 36, and
32 % respectively reporting them Bmost of the time^ or Ball
the time^.
These individuals did not use coping strategies such as
praying, meditating or relaxation, trying to distract them-
selves, or trying not think about it with 75, 61, and 57 %
respectively reporting them Bnever^ or Brarely .^
Severity The thought that it is normal to be anxious or wor-
ried about the possibility of cancer recurrence and the experi-
ence of a lot of other unpleasant thoughts or images such as
death, suffering, and consequences for family when thinking
about the possibility of cancer recurrence were most frequent-
ly reported with 61 and 52 % respectively reporting them
Bmost of the time^ or Ball the time^.
Discussion
This is one of the few studies to specifically focus on the
prevalence and features associated with FCR in CRC survi-
vors. FCR remains a significant problem for some CRC sur-
vivors even years after diagnosis, when routine follow-up care
has normally ended. This study supported the reliability and
criterion validity of the CWS in a sample of CRC survivors.
Furthermore, the CWS showed good discriminatory power
relative to the FCRI-SF, indicating that it is an appropriate
instrument to identify those individuals who experience high
FCR. Similar to the validated cut-off score in a sample of
breast cancer survivors [23], a cut-off score of 14 or higher
was optimal for differentiating a case from a non-case. With
this cut-off point, about one third (38 %) of the survivors
experienced high levels of FCR a median time of 5 years after
surgery. Levels of FCR were not different for men or women,
age, or medical characteristics. These findings are partly in
line with the recent systematic review of Simard and col-
leagues [11] which showed moderate evidence (4 studies ev-
idence; 12 studies no evidence) for a relation between FCR
and gender and only weak to moderate evidence for a relation
with disease and treatment characteristics. Although a relation
between FCR and age is often observed in the literature, there
was no significant correlation in this study. A possible expla-
nation could be that there participated both males and females
in this study. The systematic review of Simard and colleagues
[11] namely revealed that in 18 studies, of which eight includ-
ed samples of only males, no significant relationship with age
was found. It might be the case that there is no association
between age and FCR inmale cancer survivors, and therewith,
the relationship in this mixed sample disappeared.
In accordance with previous studies, the CRC survivors in
this study reported a good global quality of life [6]. However,
there were large statistically and clinically relevant differences
between individuals who reported high or low levels of FCR,
with high FCR being associated with a lower general quality
of life, lower emotional functioning, role functioning and so-
cial functioning, and more problems with body image and
future perspective. Furthermore, individuals with high FCR
had higher levels of general distress and post-traumatic stress
symptoms, such as avoidance and intrusions. This is consis-
tent with the results of studies among cancer patients reporting
that intrusive thoughts are more frequently related to future-
oriented fears, such as FCR [34–38]. Simard and colleagues
[13] revealed that the nature of these intrusive thoughts asso-
ciated with FCR shares characteristics with worries, negative
and uncontrollable thoughts on an issue whose outcome is
uncertain but which contains the possibility a negative out-
come [39]. More severe FCR tends to resemble obsession,
defined as recurrent thoughts and images, experienced as in-
trusive and inappropriate, causing anxiety and psychological
distress [40]. This was also supported by the results of this
study since CRC survivors with high FCR reported unpleasant
thoughts or images such as death, suffering, or consequences
for family when thinking about the possibility of cancer recur-
rence as one of the most frequently occurring features of FCR.
Furthermore, the results showed that high FCR is character-
ized by reactions to specific triggers, negative thoughts, and
feelings accompanied by reassurance behavior. Interestingly,
reassurance behavior mainly consisted of contact with one’s
medical professional. Body checking occurred less frequently.
An explanation for this finding might be that it is more diffi-
cult for CRC survivors to check their body for symptoms of
recurrence than for breast cancer survivors. CRC survivors
might be more focused on their defecation than on their body.
Since CRC survivors with high FCR do not experience their
fear as excessive or unreasonable (insight) but the focus seems
meanwhile to be on dysfunctional thoughts or behaviors, CRC
survivors with high FCR may benefit from cognitive behavior
therapy [41–44].
The study had some limitations. The low response rate
(38 %) and small sample size means that results might not
be representative. It is possible that survivors who have been
disease-free for a number of years might not want to think
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about hospitals and cancer research. Alternatively, it might be
the survivors with the most severe problems, with high levels
of FCR, or distress who do not participate. Despite the small
sample size, statistically and clinically relevant differences
were found between individuals with high and low levels of
FCR, and descriptive analysis was possible.
Another limitation is the difference between responders
and non-responders, which could be indicative of selection
bias. However, compared to the Dutch cancer population at
the time of this study, age categories, and gender distribution
were quite similar, indicating that is was a representative sam-
ple [45].
Although reliability and criterion validity of the CWS were
established in a population of CRC survivors, not all compo-
nents of validity were assessed. Future research should ad-
dress multiple components of validity.
Conclusions
This study emphasizes the need to focus on specific problems
rather than general QoL, but these findings should be con-
firmed with a larger sample using a prospective design. We
are currently investigating FCR, distress, and QoL in the first
year after the diagnosis of CRC. Future research should aim to
develop an evidence-based intervention for CRC survivors
with high FCR, and the results of the current study may pro-
vide starting points for such an intervention.
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